Health-related quality of life among patients with stage 3 melanoma was not significantly affected after receiving postsurgical Keytruda or placebo.
2024
GPs alongside oncologists key for melanoma outcomes
Drug therapies for the treatment of melanoma are advancing, and many now play a role for the treatment of earlier stage disease, according to new research.
FDA Grants RMAT Designation to Novel TIL Therapy OBX-115 in Melanoma
This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.
AMLo Biosciences Gets UKCA Mark for Melanoma Biomarker Test
NEW YORK — AMLo Biosciences said Tuesday that it has received UK Conformity Assessed (UKCA) marking for its AMBLor test for identifying early-stage melanomas at low risk of progression.